BD acquires Carmel Pharma

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of its acquisition of Carmel Pharma, AB, a Swedish company that manufactures the PhaSeal® System, the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials.  The acquisition expands the scope of BD's healthcare worker safety emphasis to include hazardous drug exposure reduction.

"Carmel Pharma is a leader in an early-stage market with significant long-term growth potential," said Alberto Mas, President, BD Medical – Medical Surgical Systems. "We're excited to begin moving forward to address the critically important issue of hazardous drug exposure to healthcare providers by raising awareness, driving advocacy efforts, developing pharmacy and nursing relationships, and expanding market reach around the world for this product category."

"We are pleased to welcome this new platform and these new associates to BD," said Alexandre Conroy, President, BD – Western Europe. "Healthcare worker safety is an important focus for BD in Europe, and globally. Through this acquisition, BD will be able to provide an enhanced suite of safety products to our customers."

The Company expects fully diluted earnings per share to be adversely impacted by the acquisition in fiscal year 2011 by approximately $0.05, which was not included in the fiscal year 2011 earnings guidance the Company provided in connection with the release of its third fiscal quarter earnings.

SOURCE BD (Becton, Dickinson and Company)